Option Chain

Acadia Pharmaceuticals Inc

ACADNASDAQ · USD

21.23USD-0.01 (-0.05%)

655

Acadia Pharmaceuticals Inc (ACAD) Option Chain

Acadia Pharmaceuticals Inc trades at $21.23, down 0.05%, with an IV Rank of 29.37%. This is low versus the past year, and the company carries a market cap of $3,660M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $21.00 strike shows calls at $0.65 / $1.55 and puts at $0.20 / $1.35, both carrying about $0.82 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $24.00 calls, at 100 contracts, and the $20.00 puts, at 2, as of Nov 5, 2026.

Tracking the ACAD option chain helps you see every strike and expiry on Acadia Pharmaceuticals Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ACAD options activity at a glance. Use our scanner to monitor the ACAD option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ACAD stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ACAD options are being actively traded, and where they are not.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
12.69	15	1	0.19	2.23	0.35	4.50	19.00	-10.55	0.05	0.80	0.00	0.43	0	29	87.31
27.37	269	11	0.57	1.23	1.30	2.30	20.00	-5.84	0.15	0.45	0.00	0.30	2	4,310	72.63
46.46	7,045	53	0.87	0.23	0.65	1.55	21.00	-1.13	0.20	1.35	0.00	0.78	1	70	53.54
65.54	4,019	80	0.48	0.00	0.25	0.70	22.00	+3.58	—	2.40	0.77	1.63	0	23	34.46
80.71	107	79	0.40	0.00	—	0.40	23.00	+8.29	0.10	4.00	1.77	0.28	0	19	19.29

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank29.37% Low
Market cap (M$)3,660
52 weeks high-31.40%
52 weeks low15.50%
Analyst recommendationBuy
1.71
Target price$30.68
43.81% above the current stock price
Dividend—
Payout ratio0.00%
Earnings date2026-11-04
P/E10.09
Future P/E20.64
EPS (ttm)2.10
EPS growth next 5 years-11.92%

As of Nov 5, 2026

Browse all Option Chain tickers